Investigators conducted a retrospective study of patients treated for early-stage breast cancer at Fred Hutch Cancer Center to identify clinicopathologic factors associated with SLN-positivity (SLN+), ...

JULY 2026 at 12:00 EEST Orion Group Half-Year Financial Report January-June 2026 April-June 2026 Highlights Net sales totalled EUR 521.6 (April-June ...

Net sales totalled EUR 939.3 (January-June 2025: 771.0) million Operating profit was EUR 291.3 (182.5) million Basic earnings per share were EUR 1.64 (1.02) Cash flow from operating activities per ...

Ovarian cancer has long proved difficult to treat. Could the answer lie within the disease itself? Discover how synthetic ...

The headlines were everywhere – from NPR and The Washington Post to Substack and heated exchanges on social media – all ...

Evidence supports cannabis-based therapies for a limited number of conditions. Here’'s what clinicians should know — and tell ...

In licensing Zegfrovy, AstraZeneca has gained an already approved asset, with a label expansion potentially on the horizon.

Fulgent Genetics remains a long-term play, supported by a strong balance sheet and disciplined capital allocation. Read more ...

Spain's Nuclear Safety Council has issued a favourable report on the renewal of the operating licence for the two-unit Almaraz nuclear power plant. It says the plant meets the conditions to operate ...

Thousands of people in England and Wales with a type of chronic heart failure (CHF) could soon be eligible for treatment with ...

Investors have had a moment to digest what Tempus AI (NASDAQ:TEM) actually delivered when Q1 2026 results landed on May 5.

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for ...